These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of 3-[N-(2-chlorobenzyl)amino]-6-(1H-imidazol-1-yl) pyridazine dihydrochloride on various aromatase enzyme systems and experimental breast cancer.
    Author: Bandoh K, Ishizuka Y, Sato M.
    Journal: Arzneimittelforschung; 1995 Aug; 45(8):897-900. PubMed ID: 7575757.
    Abstract:
    The effects of 3-[N-(2-chlorobenzyl)amino]-6-(1H-imidazol-1-yl)pyridazine dihydrochloride (CAS 124070-28-3, MFT-279) on various aromatase enzyme systems and experimental breast cancer were studied. MFT-279 inhibited the aromatase enzyme in vitro with an IC50 value of 2.39 nmol/l. On the other hand, MFT-279 had no effect on cytochrome P-450 dependent reactions of steroid biosynthesis. In pregnant mares' serum gonadotropin (PMSG)-treated female rats, the elevation of ovarian aromatase activity was significantly suppressed by the oral treatment with MFT-279 at 10 and 20 mg/kg. When MFT-279 (20 mg/kg) was orally given to 9,10-dimethyl-1,2-benzanthracene (DMBA)-treated female rats once a day for 28 days, regression of tumors was observed. These results suggest that MFT-279 may be useful for the endocrine therapy of hormone dependent mammary carcinoma.
    [Abstract] [Full Text] [Related] [New Search]